Wells Fargo & Company Issues Positive Forecast for Enovis (NYSE:ENOV) Stock Price

Enovis (NYSE:ENOV) had its target price raised by Wells Fargo & Company from $33.00 to $37.00 in a research note published on Friday morning,Benzinga reports. The brokerage currently has an overweight rating on the stock.

A number of other research firms have also recently commented on ENOV. Zacks Research upgraded shares of Enovis from a “strong sell” rating to a “hold” rating in a research report on Wednesday, July 29th. Citigroup reiterated a “market outperform” rating on shares of Enovis in a report on Wednesday, September 2nd. Wall Street Zen raised Enovis from a “hold” rating to a “buy” rating in a research note on Saturday, October 31st. BTIG Research boosted their target price on Enovis from $36.00 to $42.00 and gave the company a “buy” rating in a research note on Thursday. Finally, BMO Capital Markets set a $27.00 price target on Enovis in a report on Tuesday, September 1st. Ten analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $38.62.

Enovis Trading Down 5.1%

ENOV stock traded down $1.46 during trading on Friday, hitting $27.16. The company had a trading volume of 2,304,734 shares, compared to its average volume of 1,449,886. The company has a quick ratio of 1.00, a current ratio of 1.98 and a debt-to-equity ratio of 0.84. Enovis has a 12 month low of $16.70 and a 12 month high of $32.41. The stock has a market cap of $1.57 billion, a price-to-earnings ratio of -2.95 and a beta of 1.31. The firm has a 50-day moving average price of $19.91 and a 200-day moving average price of $23.09.

Enovis (NYSE:ENOV) last issued its earnings results on Thursday, November 5th. The company reported $0.88 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.77 by $0.11. The company had revenue of $558.73 million for the quarter, compared to analyst estimates of $557.12 million. Enovis had a negative net margin of 47.96% and a positive return on equity of 12.03%. The company’s revenue for the quarter was up 1.8% on a year-over-year basis. During the same quarter last year, the firm earned $0.75 EPS. As a group, analysts predict that Enovis will post 3.15 earnings per share for the current year.

Insiders Place Their Bets

In other Enovis news, insider Oliver Engert acquired 5,140 shares of Enovis stock in a transaction dated Thursday, September 3rd. The stock was bought at an average cost of $19.46 per share, for a total transaction of $100,024.40. Following the purchase, the insider directly owned 61,238 shares in the company, valued at approximately $1,191,691.48. This represents a 9.16% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Damien Mcdonald acquired 13,035 shares of Enovis stock in a transaction dated Friday, September 4th. The shares were acquired at an average price of $19.15 per share, with a total value of $249,620.25. Following the completion of the purchase, the chief executive officer owned 247,077 shares in the company, valued at approximately $4,731,524.55. The trade was a 5.57% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last ninety days, insiders purchased 23,293 shares of company stock valued at $449,599. 2.90% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in ENOV. IFP Advisors Inc raised its holdings in shares of Enovis by 5,590.5% in the 2nd quarter. IFP Advisors Inc now owns 1,195 shares of the company’s stock valued at $25,000 after purchasing an additional 1,174 shares during the period. Allworth Financial LP acquired a new position in shares of Enovis in the second quarter valued at approximately $36,000. Integrated Wealth Concepts LLC acquired a new position in shares of Enovis in the second quarter valued at approximately $39,000. Public Employees Retirement System of Ohio bought a new position in shares of Enovis during the second quarter worth approximately $48,000. Finally, SBI Securities Co. Ltd. bought a new position in shares of Enovis during the third quarter worth approximately $55,000. Institutional investors and hedge funds own 98.45% of the company’s stock.

Key Enovis News

Here are the key news stories impacting Enovis this week:

• Positive Sentiment: Q3 adjusted earnings were $0.88 per share, beating estimates of about $0.77 and topping $0.75 a year earlier. Revenue of $558.7 million slightly exceeded forecasts and grew 1.8% year over year. Enovis Q3 2026 results
• Positive Sentiment: Enovis raised its 2026 EPS guidance to $3.58–$3.79, signaling improved earnings expectations. Guidance and repurchase announcement
• Positive Sentiment: The company authorized a $200 million share-repurchase program, which could support per-share results and signal confidence in its prospects. Share-buyback announcement
• Positive Sentiment: Wells Fargo raised its target to $37 and maintained an Overweight rating; Needham lifted its target to $38 and BTIG to $42, both with Buy ratings. Wells Fargo analyst rating
• Neutral Sentiment: Canaccord lowered its price target from $45 to $42 but kept a Buy rating. Reports also highlighted product innovation and market-share gains, though market volatility remains a factor. Product innovation and share gains

About Enovis

Enovis Corporation (NYSE: ENOV) is a medical technology company that develops, manufactures and distributes products designed to improve patient recovery, mobility and quality of life. Its portfolio serves orthopedic, sports medicine, physical therapy and rehabilitation markets, as well as other areas of musculoskeletal care.

The company’s products include orthopedic implants and surgical technologies, braces and supports, cold and compression therapy systems, electrotherapy and rehabilitation equipment, and other solutions used by hospitals, surgeons, physical therapists, athletic trainers and patients.